MX2022006381A - Metodo para generar celulas inmunoreguladoras en una muestra derivada de sangre. - Google Patents
Metodo para generar celulas inmunoreguladoras en una muestra derivada de sangre.Info
- Publication number
- MX2022006381A MX2022006381A MX2022006381A MX2022006381A MX2022006381A MX 2022006381 A MX2022006381 A MX 2022006381A MX 2022006381 A MX2022006381 A MX 2022006381A MX 2022006381 A MX2022006381 A MX 2022006381A MX 2022006381 A MX2022006381 A MX 2022006381A
- Authority
- MX
- Mexico
- Prior art keywords
- sample
- irradiation
- immunoregulatory
- cells
- blood
- Prior art date
Links
- 230000004957 immunoregulator effect Effects 0.000 title abstract 4
- 210000004369 blood Anatomy 0.000 title abstract 3
- 239000008280 blood Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 210000000822 natural killer cell Anatomy 0.000 abstract 3
- 239000003504 photosensitizing agent Substances 0.000 abstract 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 abstract 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical group C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 229960004469 methoxsalen Drugs 0.000 abstract 1
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0066—Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
- C12N2529/10—Stimulation by light
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención hace referencia a un método que comprende las etapas de proveer una muestra derivada de una muestra de sangre de un sujeto que ha recibido una terapia de inhibidores de puntos de control y se sospecha que pueda desarrollar o ha desarrollado síntomas de eventos adversos relacionados con la inmunidad (irAE), de forma que agrega un agente de fotosensibilización a la muestra y somete la muestra a radiación, lo que genera, preferentemente, linfocitos NK inmunoreguladores en la muestra. En modalidades, el agente de fotosensibilización es 8-metoxipsoraleno y/o la radiación es radiación UVA. En otro aspecto, la invención hace referencia a los linfocitos NK inmunoreguladores obtenidos de un método que comprende las etapas de proveer una muestra derivada de una muestra de sangre aislada de un sujeto, de forma de agregar un agente de fotosensibilización a la muestra y someter la muestra a radiación. Además, la invención comprende linfocitos NK inmunoreguladores para su uso en el tratamiento y/o la prevención de irAE en un sujeto que ha recibido una terapia inhibidora de puntos de control.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19218724 | 2019-12-20 | ||
| PCT/EP2020/086733 WO2021122969A1 (en) | 2019-12-20 | 2020-12-17 | Method for generating immunoregulatory cells in a blood-derived sample |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006381A true MX2022006381A (es) | 2022-06-24 |
Family
ID=69005255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006381A MX2022006381A (es) | 2019-12-20 | 2020-12-17 | Metodo para generar celulas inmunoreguladoras en una muestra derivada de sangre. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230024405A1 (es) |
| EP (2) | EP4374876A2 (es) |
| JP (1) | JP2023506413A (es) |
| KR (1) | KR20220118404A (es) |
| CN (1) | CN114901809A (es) |
| AU (1) | AU2020404121A1 (es) |
| BR (1) | BR112022010129A2 (es) |
| CA (1) | CA3164882A1 (es) |
| IL (1) | IL293773A (es) |
| MX (1) | MX2022006381A (es) |
| WO (1) | WO2021122969A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4389122A1 (en) * | 2022-12-21 | 2024-06-26 | Mallinckrodt Pharmaceuticals Ireland Limited | Adiponectin alone or in combination with extracorporeal photopheresis (ecp) for immune related adverse events of immune checkpoint inhibitors |
| WO2024134596A1 (en) * | 2022-12-21 | 2024-06-27 | Mallinckrodt Pharmaceuticals Ireland Limited | Adiponectin alone or in combination with extracorporeal photopheresis (ecp) for immune related adverse events of immune checkpoint inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997036581A1 (en) | 1996-03-29 | 1997-10-09 | Therakos, Inc. | Photopheresis treatment of leukocytes |
| EP0994743B1 (en) * | 1997-07-10 | 2006-05-31 | Therakos, Inc. | Treatment of inflammatory disorders of the bowel or urinary bladder |
-
2020
- 2020-12-17 BR BR112022010129A patent/BR112022010129A2/pt unknown
- 2020-12-17 CA CA3164882A patent/CA3164882A1/en active Pending
- 2020-12-17 JP JP2022534200A patent/JP2023506413A/ja active Pending
- 2020-12-17 WO PCT/EP2020/086733 patent/WO2021122969A1/en unknown
- 2020-12-17 EP EP24167613.9A patent/EP4374876A2/en active Pending
- 2020-12-17 US US17/787,836 patent/US20230024405A1/en active Pending
- 2020-12-17 MX MX2022006381A patent/MX2022006381A/es unknown
- 2020-12-17 AU AU2020404121A patent/AU2020404121A1/en active Pending
- 2020-12-17 CN CN202080086877.0A patent/CN114901809A/zh active Pending
- 2020-12-17 EP EP20833822.8A patent/EP4077639B1/en active Active
- 2020-12-17 IL IL293773A patent/IL293773A/en unknown
- 2020-12-17 KR KR1020227017635A patent/KR20220118404A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230024405A1 (en) | 2023-01-26 |
| KR20220118404A (ko) | 2022-08-25 |
| WO2021122969A1 (en) | 2021-06-24 |
| EP4077639B1 (en) | 2024-06-12 |
| EP4374876A2 (en) | 2024-05-29 |
| IL293773A (en) | 2022-08-01 |
| CA3164882A1 (en) | 2021-06-24 |
| CN114901809A (zh) | 2022-08-12 |
| JP2023506413A (ja) | 2023-02-16 |
| BR112022010129A2 (pt) | 2022-08-09 |
| EP4077639A1 (en) | 2022-10-26 |
| AU2020404121A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006381A (es) | Metodo para generar celulas inmunoreguladoras en una muestra derivada de sangre. | |
| Bramhall et al. | Speech perception ability in noise is correlated with auditory brainstem response wave I amplitude | |
| WO2016201450A3 (en) | Cancer treatment and diagnosis | |
| CO2017000571A2 (es) | Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena | |
| WO2007030124A3 (en) | Treatment screening methods | |
| WO2016196298A8 (en) | Therapeutic and diagnostic methods for cancer | |
| EA201391587A1 (ru) | Комбинированная терапия на основе hsp90 | |
| Vetulani et al. | Chronic electroconvulsive treatment enhances the density of [3H] prazosin binding sites in the central nervous system of the rat | |
| DE602004032340D1 (de) | Verfahren zur behandlung von lentivirusinfektionen | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| MX2021006578A (es) | Procedimientos de diagnostico y composiciones para la inmunoterapia contra el cancer. | |
| AU2018329925A8 (en) | Diagnostic and therapeutic methods for cancer | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| MX2019015841A (es) | Celulas inmunes defectuosas para suv39h1. | |
| Chhikara et al. | Carbon monoxide blocks lipopolysaccharide-induced gene expression by interfering with proximal TLR4 to NF-κB signal transduction in human monocytes | |
| MX2020012939A (es) | Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios. | |
| CO2022003582A2 (es) | Métodos para el tratamiento de la oftalmopatía tiroidea | |
| Chaabna et al. | Kaposi sarcoma trends in Uganda and Zimbabwe: a sustained decline in incidence? | |
| EA202190474A1 (ru) | Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей | |
| MX2023006488A (es) | Procedimientos y composiciones para el tratamiento neoadyuvante y adyuvante del carcinoma urotelial. | |
| Kobashigawa et al. | Relief of delayed oxidative stress by ascorbic acid can suppress radiation-induced cellular senescence in mammalian fibroblast cells | |
| EA201892542A1 (ru) | Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19 | |
| da Silva Oliveira et al. | Photobiomodulation induces antinociception, recovers structural aspects and regulates mitochondrial homeostasis in peripheral nerve of diabetic mice | |
| CL2021002854A1 (es) | Método para la predicción de eficacia del tratamiento de hemoglobinopatía | |
| Parrondo et al. | Efficacy of autologous and allogeneic hematopoietic cell transplantation in Waldenström macroglobulinemia: a systematic review and meta-analysis |